BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 34030872)

  • 1. Entecavir Monotherapy Prevents Hepatitis B Virus Recurrence After Liver Transplant for Chronic Hepatitis B Patients: A Long-Term Retrospective Study.
    Liu Y; Ho WI; Deng F; Peng S; Lau WY; Chen H
    Transplant Proc; 2021 Jun; 53(5):1700-1706. PubMed ID: 34030872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years.
    Fung J; Wong T; Chok K; Chan A; Cheung TT; Dai JW; Sin SL; Ma KW; Ng K; Ng KT; Seto WK; Lai CL; Yuen MF; Lo CM
    Hepatology; 2017 Oct; 66(4):1036-1044. PubMed ID: 28370215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
    Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral treatment for hepatitis B virus recurrence following liver transplantation.
    Lee S; Kwon CH; Moon HH; Kim TS; Roh Y; Song S; Shin M; Kim JM; Park JB; Kim SJ; Joh JW; Lee SK
    Clin Transplant; 2013; 27(5):E597-604. PubMed ID: 24093615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients.
    Urabe A; Imamura M; Tsuge M; Kan H; Fujino H; Fukuhara T; Masaki K; Kobayashi T; Ono A; Nakahara T; Kawaoka T; Hiramatsu A; Kawakami Y; Aikata H; Hayes CN; Maki N; Ohdan H; Chayama K
    J Gastroenterol; 2017 Mar; 52(3):366-375. PubMed ID: 27422771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B.
    Perrillo R; Buti M; Durand F; Charlton M; Gadano A; Cantisani G; Loong CC; Brown K; Hu W; Lopez-Talavera JC; Llamoso C
    Liver Transpl; 2013 Aug; 19(8):887-95. PubMed ID: 23788462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
    Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
    Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment.
    Seto WK; Lam YF; Fung J; Wong DK; Huang FY; Hung IF; Lai CL; Yuen MF
    J Gastroenterol Hepatol; 2014 May; 29(5):1028-34. PubMed ID: 24325451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis in liver transplantation recipients after hepatitis B virus recurrence.
    Sun LY; Zhu ZJ; Qu W; Sun XY; Rao W; Liu Y
    Hepatogastroenterology; 2014 Oct; 61(135):2047-51. PubMed ID: 25713909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load.
    Huang G; Yang Y; Shen F; Pan ZY; Fu SY; Lau WY; Zhou WP; Wu MC
    Ann Surg Oncol; 2013 May; 20(5):1482-90. PubMed ID: 23247982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
    Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK
    Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
    J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of Preoperative Antiviral Treatment of Patients with HCC Negative for HBV-DNA.
    Liu XF; Zhang T; Tang K; Sui LL; Xu G; Liu Q
    Anticancer Res; 2017 Aug; 37(8):4701-4706. PubMed ID: 28739774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma.
    Viganò M; Bhoori S; Lampertico P; Donato MF; Iavarone M; Grossi G; Facciorusso A; Caccamo L; Rossi G; Colombo M; Mazzaferro V
    Liver Int; 2015 Sep; 35(9):2187-93. PubMed ID: 25809541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
    Choudhary NS; Saraf N; Saigal S; Mohanka R; Rastogi A; Goja S; Menon PB; Soin AS
    Transpl Infect Dis; 2015 Jun; 17(3):329-33. PubMed ID: 25682715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
    Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
    Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.